OAC
KLRS

OMERS Administration Corp’s Kalaris Therapeutics KLRS Stock Holding History

OMERS Administration Corp’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$253K – 1194
2025
Q4 		$253K Buy
+30,000
New +$192K ﹤0.01% 857

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

OMERS Administration Corp's KLRS Position: Q1 2026 in Review

OMERS Administration Corp sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 30,000 shares — an estimated $253K sold.

OMERS Administration Corp first reported a position in KLRS in Q4 2025 and held it in 1 quarter. The position peaked at $253K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • OMERS Administration Corp reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 30,000 Kalaris Therapeutics shares in Q1 2026, an estimated $253K.
  • OMERS Administration Corp first reported a position in Kalaris Therapeutics in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Kalaris Therapeutics position peaked at $253K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.